Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591722 | 0.89 | HPGD (0.52) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL593874 | 0.88 | DRD2 (0.49) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL591973 | 0.85 | ADRA1D (0.53) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL593713 | 0.85 | HPGD (0.65) | ADRA1DADRA1AADRA1BHPGD | |
| SCHEMBL592220 | 0.84 | HPGD (0.48) | SIGMAR1ADRA1DADRA1AADRA1BHPGD | |
| SCHEMBL593213 | 0.84 | ADRA1D (0.50) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL593080 | 0.83 | DRD2 (0.52) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL593377 | 0.83 | KDM4E (0.53) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL593818 | 0.83 | TK2 (0.53) | DRD2DRD3ADRA1DADRA1AADRA1B | |
| SCHEMBL593275 | 0.83 | SIGMAR1 (0.49) | SIGMAR1DRD2DRD3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828146-B1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2014-11-05 | — | — | EP | claimed |
| EP-1828146-B1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8114875-B2 | Substituted N-heterocyclic compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20090054449-A1 | Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054449-A1 | Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands | SLC6A3, DRD3, HTR3A | SIGMAR1 185/4885DRD2 5/4885DRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.